AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25406966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (6000 IU/day for 3 months, then 3000 IU/day for 3 months)
Number of subjects: 87
Study 25406966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 25406966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 87
Study 25406966 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 supplementation and Placebo
Number of subjects: 87
Study 23387320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nutrition treatment
Number of subjects: 324
Study 23387320 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition education
Number of subjects: 324
Study 22027241 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 129
Study 22027241 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 129
Study 18096910 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (animated GIF)
Number of subjects: 6500
Study 18096910 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (static image)
Number of subjects: 6500
Study 18096910 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (HTML text)
Number of subjects: 6500
Study 18096910 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (artwork text)
Number of subjects: 6500
Study 18096910 — intervention group
Group type: COMPARATOR
Intervention: courier plain text message
Number of subjects: 6500
Study 16943584 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt hypothyroidism group
Number of subjects: 41
Study 16943584 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism group
Number of subjects: 41
Study 16943584 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels higher than 5 microIU/mL
Number of subjects: 41
Study 16943584 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 14600050 — intervention group
Group type: EXPERIMENTAL
Intervention: Network condition
Number of subjects: 1961
Study 14600050 — intervention group
Group type: COMPARATOR
Intervention: Random condition
Number of subjects: 1961
Study 14600050 — intervention group
Group type: COMPARATOR
Intervention: Teacher condition
Number of subjects: 1961
Study 10602102 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes in ischemic central retinal vein occlusion (n=18)
Number of subjects: 102
Study 10602102 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes in nonischemic central retinal vein occlusion (n=51)
Number of subjects: 102
Study 10602102 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes in branch retinal vein occlusion (n=33)
Number of subjects: 102
Study 10602102 — intervention group
Group type: COMPARATOR
Intervention: Control subjects' eyes
Number of subjects: 102
Study 9351763 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg)
Number of subjects: 103
Study 9351763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 9351763 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful versions (both groups)
Number of subjects: 103
Study 9351763 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed versions (both groups)
Number of subjects: 103
Study 8416148 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 0
Study 8416148 — intervention group
Group type: EXPERIMENTAL
Intervention: combinations of autologous blood use with various rHuEPO regimens
Number of subjects: 0
Study 3621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (1 micrograms/kg/min by i.v. infusion)
Number of subjects: 5
Study 3621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (10(‐5) mol/l) in vitro
Number of subjects: 5
Study 3621618 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 5
Study 3621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (10(‐9) mol/l‐10(‐5) mol/l) in vitro
Number of subjects: 5
Study 29408797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol + Clopidogrel (n=24)
Number of subjects: 46
Study 29408797 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone (n=22)
Number of subjects: 46
Study 29408797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 46
Study 29408797 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus
Number of subjects: 46
Study 29408797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit
Number of subjects: 46
Study 25782020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy with methylprednisolone (500 mg daily intravenous for 3 days, followed by 1 mg/kg oral prednisolone for 11 days)
Number of subjects: 67
Study 25782020 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral prednisolone therapy (1 mg/kg oral prednisolone for 14 days)
Number of subjects: 67
Study 25782020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pulse therapy and traditional therapy)
Number of subjects: 67
Study 26677666 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Yangyin Recipe (QRYYR), one dose per day in two portions, once in the morning and once in the evening.
Number of subjects: 90
Study 26677666 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg, twice per day for 3 consecutive months.
Number of subjects: 90
Study 26677666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (QRYYR and Metformin for the first month, then QRYYR for two months).
Number of subjects: 90
Study 26677666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs group (QRYYR).
Number of subjects: 90
Study 26677666 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (Metformin).
Number of subjects: 90
Study 23921769 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS training on approximate addition and subtraction of arrays of dots
Number of subjects: 0
Study 23921769 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS training
Number of subjects: 0
Study 20206783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 18
Study 20206783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 18
Study 20206783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 18
Study 17968028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 40 mg/day to 80 mg/day (n = 271)
Number of subjects: 410
Study 17968028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 139)
Number of subjects: 410
Study 15722000 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Cognitive Behavioral Therapy (fCBT)
Number of subjects: 30
Study 15722000 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 30
Study 12706357 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tamoxifen (n=16)
Number of subjects: 56
Study 12706357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tamoxifen (n=14)
Number of subjects: 56
Study 12706357 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tamoxifen (n=15)
Number of subjects: 56
Study 12706357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 56
Study 11049785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vancomycin (2 g/day) combined with Saccharomyces boulardii (1 g/day for 28 days)
Number of subjects: 0
Study 11049785 — intervention group
Group type: COMPARATOR
Intervention: High-dose vancomycin (2 g/day) combined with placebo
Number of subjects: 0
Study 8781465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma vitamin E level (lowest quartile)
Number of subjects: 410
Study 8781465 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked daily
Number of subjects: 410
Study 1535400 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0
Study 1535400 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine with 3.0 ng/kg/min Ang II
Number of subjects: 0
Study 1535400 — intervention group
Group type: COMPARATOR
Intervention: Felodipine after placebo pretreatment
Number of subjects: 0
Study 1535400 — intervention group
Group type: COMPARATOR
Intervention: Felodipine after ramipril pretreatment
Number of subjects: 0
Study 6494835 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotraction
Number of subjects: 49
Study 6494835 — intervention group
Group type: COMPARATOR
Intervention: Manual traction
Number of subjects: 49
Study 6494835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 49
Study 30883058 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with transfemoral placement of a balloon-expandable valve
Number of subjects: 1000
Study 30883058 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1000
Study 30883058 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1000
Study 29037578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine at 10 mcg
Number of subjects: 60
Study 29037578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine at 6 mcg
Number of subjects: 60
Study 29037578 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 mcg, and 3 mcg recipients
Number of subjects: 60
Study 29037578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine (all doses)
Number of subjects: 60
Study 29037578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine
Number of subjects: 60
Study 24756324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode 808-nm laser-assisted treatment
Number of subjects: 10
Study 24756324 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 10
Study 24961183 — intervention group
Group type: EXPERIMENTAL
Intervention: MG + MT
Number of subjects: 16
Study 24961183 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 16
Study 22085729 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle (ASB) reconstruction
Number of subjects: 320
Study 22085729 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle (ADB) reconstruction
Number of subjects: 320
Study 22085729 — intervention group
Group type: COMPARATOR
Intervention: Conventional single-bundle (CSB) reconstruction
Number of subjects: 320
Study 19547802 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (200,000 IU)
Number of subjects: 85
Study 19547802 — intervention group
Group type: COMPARATOR
Intervention: Control (0 IU)
Number of subjects: 85
Study 17923542 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with alpha‐l‐iduronidase (Aldurazyme)
Number of subjects: 8
Study 15200537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound visualisation
Number of subjects: 40
Study 15200537 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 40
Study 16027532 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Telemedicine Units (HTUs) installation and training by registered nurses (RNs)
Number of subjects: 0
Study 16027532 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-related problems during installation
Number of subjects: 0
Study 10327509 — intervention group
Group type: EXPERIMENTAL
Intervention: deamino‐8‐D‐arginin vasopressin (0.3 microgram/kg body weight; maximum, 20 micrograms)
Number of subjects: 35
Study 10327509 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 10327509 — intervention group
Group type: EXPERIMENTAL
Intervention: deamino‐8‐D‐arginin vasopressin
Number of subjects: 35
Study 8723394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 17
Study 8723394 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 17
Study 1718119 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (dose of 10(-9) - 10(-11) mol)
Number of subjects: 40
Study 1718119 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (dose of 10(-10) mol)
Number of subjects: 40
Study 1718119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard oil (two concentrations)
Number of subjects: 40
Study 7183186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administration/cigarette smoking
Number of subjects: 0
Study 7183186 — intervention group
Group type: COMPARATOR
Intervention: Control (non-smokers)
Number of subjects: 0
Study 30982631 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment group
Number of subjects: 285
Study 30982631 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin-guided care group
Number of subjects: 285
Study 28970180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost model
Number of subjects: 14
Study 28970180 — intervention group
Group type: COMPARATOR
Intervention: Cadaver
Number of subjects: 14
Study 27025001 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 186
Study 27025001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational video)
Number of subjects: 186
Study 25457418 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ training
Number of subjects: 132
Study 25457418 — intervention group
Group type: COMPARATOR
Intervention: Control group (straight-line sprint training)
Number of subjects: 132
Study 23229960 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Professional Development (CPD) workshops
Number of subjects: 100
Study 23229960 — intervention group
Group type: COMPARATOR
Intervention: Traditional Continuing Pharmacy Education (CPE)
Number of subjects: 100
Study 20627197 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous chloride-containing fluoride solution (800 ppm Sn(II), 500 ppm F, pH 4.5)
Number of subjects: 120
Study 20627197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride solution (500 ppm F, pH 4.5)
Number of subjects: 120
Study 20627197 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 120
Study 17717202 — intervention group
Group type: EXPERIMENTAL
Intervention: GW274150 (90 mg)
Number of subjects: 28
Study 17717202 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 28
Study 17717202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15785093 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (6 MIU intramuscularly daily for 2 weeks, then three times a week for 14 weeks, and finally twice a week for 88 weeks)
Number of subjects: 30
Study 15785093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 11899189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2.5 minimum alveolar concentration) during the first 10 minutes of cardiopulmonary bypass (CPB)
Number of subjects: 20
Study 11899189 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane-free CPB)
Number of subjects: 20
Study 10446040 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help intervention (n = 288) including a self-help booklet, a smoking and reproductive health information card, and three telephone counseling calls.
Number of subjects: 580
Study 10446040 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 292)
Number of subjects: 580
Study 10446040 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help intervention (n = 288) among women with an abnormal Pap test result.
Number of subjects: 580
Study 10446040 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 292) among women with an abnormal Pap test result.
Number of subjects: 580
Study 7595818 — intervention group
Group type: EXPERIMENTAL
Intervention: Child behavioral information
Number of subjects: 108
Study 7595818 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role information
Number of subjects: 108
Study 31561351 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsy (Fbx)
Number of subjects: 234
Study 28841064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hernia Repair Education Intervention (HREI)
Number of subjects: 82
Study 28841064 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study 25460030 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) sublingually combined with PDE5 inhibitor sildenafil (50 mg)
Number of subjects: 21
Study 25460030 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) sublingually combined with serotonin (5-HT)1A receptor agonist buspirone (10 mg)
Number of subjects: 21
Study 22903517 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminous biofeedback (LB group)
Number of subjects: 30
Study 22903517 — intervention group
Group type: COMPARATOR
Intervention: Acoustic biofeedback (AB group)
Number of subjects: 30
Study 21940420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant given 2 days after vaccine (group T5)
Number of subjects: 70
Study 21940420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent with vaccine (group T4)
Number of subjects: 70
Study 18040163 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV incidence among men
Number of subjects: 3881
Study 18040163 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV incidence among women
Number of subjects: 3881
Study 18040163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual behaviour change
Number of subjects: 3881
Study 18040163 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention strategies effectiveness
Number of subjects: 3881
Study 16109160 — intervention group
Group type: EXPERIMENTAL
Intervention: Five pound voucher redeemable at many high street stores
Number of subjects: 722
Study 16109160 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 722
Study 12031745 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil-propofol
Number of subjects: 40
Study 12031745 — intervention group
Group type: COMPARATOR
Intervention: alfentanil-propofol
Number of subjects: 40
Study 10625102 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of amoxicillin orally daily for 5 days postoperatively, starting at the completion of surgery
Number of subjects: 141
Study 10625102 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 141
Study 8530624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rhIGF-I, sc, twice daily
Number of subjects: 16
Study 1673976 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg, daily for 2 weeks
Number of subjects: 10
Study 1673976 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identical to astemizole, daily for 2 weeks
Number of subjects: 10
Study 1673976 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 10
Study 1673976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 60
Study 7102709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir and dilute steroid drops
Number of subjects: 60
Study 30025502 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfinance and health leadership intervention
Number of subjects: 0
Study 29952619 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + SFAS
Number of subjects: 82
Study 29952619 — intervention group
Group type: COMPARATOR
Intervention: BMI + RT
Number of subjects: 82
Study 29952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 82
Study 26430929 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic bread containing Lactobacillus sporogenes (1 × 10^8 CFU) and 0.07 g inulin per 1 g
Number of subjects: 81
Study 26430929 — intervention group
Group type: COMPARATOR
Intervention: Probiotic bread containing Lactobacillus sporogenes (1 × 10^8 CFU)
Number of subjects: 81
Study 26430929 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 81
Study 24186848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received repeated individual and group counseling on healthy lifestyles and guided antihypertensive therapy based on home BP measurements.
Number of subjects: 220
Study 24186848 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard care without the comprehensive intervention.
Number of subjects: 220
Study 21530322 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty with varying humeral versions (0°, 10°, 20° retroversion) and implant thicknesses (‐3, 0, +3 mm from baseline)
Number of subjects: 0
Study 21530322 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty
Number of subjects: 0
Study 19403551 — intervention group
Group type: EXPERIMENTAL
Intervention: Self- and manual mobilization (1 hour twice a week for 8 weeks)
Number of subjects: 32
Study 19403551 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 17653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (0.64 ml) in a test meal (200 kcal per 200 ml)
Number of subjects: 10
Study 17653649 — intervention group
Group type: COMPARATOR
Intervention: Test meal alone (control)
Number of subjects: 10
Study 15621316 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous low back compression loads for men
Number of subjects: 10
Study 15621316 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous low back compression loads for women
Number of subjects: 10
Study 15621316 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cumulative load for males
Number of subjects: 10
Study 15621316 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cumulative load for females
Number of subjects: 10
Study 11983635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 32
Study 10450007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear Matrix Protein 22 (NMP22) test
Number of subjects: 140
Study 10450007 — intervention group
Group type: EXPERIMENTAL
Intervention: BTA stat test
Number of subjects: 140
Study 10450007 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 140
Study 7661124 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented men (20 mg Fe/d)
Number of subjects: 36